Lisdexamfetamine and mood disorders: a systematic review
DOI:
https://doi.org/10.25118/2236-918X-7-5-2Keywords:
Bipolar disorder, depressive disorder, lisdexamfetamine dimesylateAbstract
The present study is a systematic review of the literature published in the MEDLINE database to evaluate the effects and safety profile of lisdexamfetamine (LDX) use in patients with depressive disorder (DD) and bipolar disorder (BD), using only medical subject headings (MeSH). The following terms were used: “depressive disorder” [MeSH] OR “bipolar disorder” [MeSH] AND“ lisdexamfetamine dimesylate” [MeSH]. We selected articles published in Portuguese and English only, with no publication date restrictions. As an inclusion criterion, only articles that observed the profile of effects of LDX use in patients with mood disorders, with or without comorbid attention deficit and hyperactivity disorder, were included. Eight papers were selected, but only five were included in the narrative synthesis. We found few data on the use of LDX in mood disorders, but the results demonstrate a possible use to potentiate treatment and reduce cognitive impairment in patients with DD, as well as to improve metabolic syndrome parameters in patients with BD.
Downloads
Metrics
References
Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease control priorities in developing countries. 2nd ed. Washington: World Bank; 2006. p. 605-11.
Sarin L. Clasificación y evolución de la enfermedad depresiva. In: Grupo De Psiquiatras Latinoamericanos para la Docencia em Depresión. Diagnóstico y tratamiento de la enfermedad depresiva. México: AWWE; 2013. p. 35-42.
Sarin L, Duailibi K. Diagnóstico e tratamento da depressão: a multidimensionalidade do transtorno depressivo maior: alcançando a remissão dos sintomas físicos, emocionais e a funcionalidade plena do paciente. São Paulo: Planmark; 2013.
Justo LP, Calil HM. Depressão - o mesmo acometimento para homens e mulheres? Rev Psiquiatr Clin. 2006;33:74-9.
Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry. 2013;74:802-9.
Stahl SM. Psicofarmacologia: bases neurocientíficas e aplicações práticas. 3ª ed. Rio de Janeiro: Guanabara Koogan; 2010. Cap. 17, p. 591-601.
Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139:81-132.
Rocca CC, Lafer B. [Neuropsychological disturbances in bipolar disorder]. Rev Bras Psiquiatr. 2006;28:226-37.
Harvey PD, Roth RM, Bilder RM, Richards C, Lasser R, Geibel B, et al. Assessment of executive dysfunction in adults with major depressive disorder receiving lisdexamfetamine dimesylate augmentation of escitalopram. In: 165th Annual Meeting of the American Psychiatric Association; 2012 May 5–9; Philadelphia, USA.
Associação Americana de Psiquiatria. Manual Diagnóstico e Estatístico de Transtornos Mentais, 5ª edição (DSM-5). Porto Alegre: Artmed; 2014.
McIntyre RS, Alsuwaidan M, Soczynska JK, Szpindel I, Bilkey TS, Almagor D, et al. The effect of Lisdexamfetamine Dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013;28:421-7.
Muneer A. The treatment of adult bipolar disorder with aripiprazole: a systematic review. Cureus; 2016;8:e562.
Howland RH. The use of dopaminergic and stimulant drugs for the treatment of depression. J Psychosoc Nurs Ment Health Serv. 201250:11-4.
Kollins SH, Youcha S, Lasser R, Thase ME. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innov Clin Neurosci. 2011;8:28-32.
Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebocontrolled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364-73.
Wolraich ML, Wibbelsman CJ, Brown TE, Evans SW, Gotlieb EM, Knight JR, et al. Attentiondeficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734-46.
Andrade ER, Louzã Neto MR. Psicofarmacologia em psiquiatria: psicoestimulantes. In: Miguel EC, Gentil V, Gattaz WF. Clínica psiquiátrica. São Paulo: Manole. 2011. p. 1232-35.
Stahl SM. Psicofarmacologia: bases neurocientíficas e aplicações práticas. 3ª ed. Rio de Janeiro: Guanabara Koogan; 2010. Cap. 9, p. 10:218-300.
Relja MM, Sachdev M. Review of clinical handbook of psychotropic drugs for children and adolescents, 3rd Ed., edited by Dean Elbe, Kalyna Z. Bezchlibnyk-Butler, Adil S. Virani, and Ric M. Procyshyn. J Child Adolesc Psychopharmacol. 2016;26:493-4.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
McElroy SL, Martens BE, Mori N, Blom TJ, Casuto LS, Hawkins JM, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30:6-13.
Madhoo M, Keefe RS, Roth RM, Sumbunaris A, Wu J, Trivedi MH, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39:1388-98.
Rabin LA, Roth RM, Isquith PK, Wishart HA, Nutter-Upham KE, Pare N, et al. Self- and informant report executive function on the BRIEF-A in MCI and older adults with cognitive complaints. Arch Clin Neuropsychol. 2006;21:721-32.
Roth RM, Isquith PK, Gioia GA. Behavior rating inventory of executive function-adult version (BRIEF-A) professional manual. Lutz: Psychological Assessment Resources; 2005.
Macêdo DS, de Lucena DF, Queiroz AI, Cordeiro RC, Araújo MM, Sousa FC, et al. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:230-7.
Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171:1067-73.
Bai YM, Li CT, Tsai SJ, Tu PC, Chen MH, Su TP. Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder. BMC Psychiatry. 2016;16:448.
McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, et al. Bipolar disorder andmetabolic syndrome: an international perspective. J Affect Disord. 2010;126:366-87.
Grover S, Malhotra N, Chakrabarti S, Kulhara P. Metabolic syndrome in bipolar disorders. Indian J Psychol Med. 2012;34:110-8.
Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59:1175-83.
Hui Poon S, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol. 2015;13:592-604.
Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18:143-57.
Abbasowa L, Kessing LV, Vinberg M. Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials. Nord J Psychiatry. 2013;67:369-82.
Hammar A, Ardal G. Cognitive functioning in major depression -- a summary. Front Hum Neurosci. 2009;3:26.
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029-40.
Bender A. Restoring function in MDD: balancing efficacy and tolerability to optimally manage major depressive disorder. Can J Diagn. 2011;1:13-20.
Ciolac EG, Guimarães GV. Exercício físico e síndrome metabólica. Rev Bras Med Esporte. 2004;10:319-24.
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
